The percentages of increased NLR (55.5 vs. 31.7%; p = 0.049), lymphopenia (55.5 vs. 31.7%; p = 0.049), increased SAA (75 vs. 38.5%; p = 0.059), increased CRP (58.3 vs. 26.9%; p = 0.061), and increased IgG antibody (84.2 vs. 76.7%; p = 0.743) and IgM antibody (73.6 vs. 60.4%; p = 0.316) were higher in COVID-19 patients with GI symptoms than in those without GI symptoms, although some test results showed no significant differences. The gene discussed is CD40LG; the disease is COVID-19.